top of page
  • Writer's pictureBerke Search

The Berke Report: M&A Updates for the First Week of May 2023

Magenta Therapeutics And Dianthus Therapeutics Announce Merger Agreement (PR)

Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics. Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus’ new and existing investors, which is expected to provide funding into mid-2026. Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2


Eterna Therapeutics Acquires Exacis’ Allogeneic Immuno-Oncology Platform (genengnews)

Eterna Therapeutics acquired the global immuno-oncology platform of Exacis Biotherapeutics. Eterna officials say the acquisition complements the company’s core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors. The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs).

Eyeing Its Next Blockbuster, Astellas Lines Up $5.9B Iveric Bio Acquisition (medcitynews)

Under terms of the deal announced Sunday evening, Tokyo-based Astellas will pay $40 cash for each share of Iveric. That price represents a 21.6% premium to the stock’s closing price on Friday. But the biotech’s share had already been on a steady climb since mid-February when FDA approval of a rival drug provided validation for Iveric’s approach. The agency that month also accepted Iveric’s new drug application, setting an August 19 target date for a decision on the biotech’s drug, avacincaptad pegol.

4 views0 comments

Recent Posts

See All

The Berke Report: Medical Device Update

Raises: Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield (PR) Tampa-based PainTEQ, a medical device company seeking to treat lower back pain, says it has closed on a new round of $

The Berke Report: Clinical and Commercial Updates

Commercial: FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy. The disease occurs in up to one in every 5,000 newborn males worldwide (pmlive) FDA Approves Pfizer’s


bottom of page